On Mar. 5, 2021, Abbott announced FDA Emergency Use Authorization (EUA) for the company’s Alinityﾙ m Resp-4-Plex molecular assay to detect and differentiate SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus (RSV) in one test. This is an important tool because these viruses have similar symptoms but require different treatment approaches. This test was CE Marked and available in countries outside the U.S.